About the journal
The Revista Brasileira de Ginecologia e Obstetrícia is a scientific publication of the Brazilian Federation of Gynecology and Obstetrics Associations (FEBRASGO). It is aimed at gynecologists, obstetricians and professionals in related areas with the purpose to publish research results on relevant topics in the field of Gynecology, Obstetrics and related areas.
-
Febrasgo Position Statement
Hyperprolactinemia in women: diagnostic approach
- Andrea Glezer
, - Heraldo Mendes Garmes ,
- Leandro Kasuki ,
- Manoel Martins ,
- Paula Condé Lamparelli Elias , [ … ],
- Andrea Prestes Nácul
Summary
Febrasgo Position StatementHyperprolactinemia in women: diagnostic approach
Rev Bras Ginecol Obstet. 2024;46:e-FPS04
Views701
Summary
Febrasgo Position StatementHyperprolactinemia in women: diagnostic approach
Rev Bras Ginecol Obstet. 2024;46:e-FPS04
- Andrea Glezer
-
Febrasgo Position Statement
Hyperprolactinemia in women: treatment
- Cristina Laguna Benetti-Pinto ,
- Andrea Prestes Nácul ,
- Ana Carolina Japur Rosa e Silva ,
- Gustavo Arantes Rosa Maciel ,
- Vania dos Santos Nunes Nogueira , [ … ],
- Andrea Glezer
Summary
Febrasgo Position StatementHyperprolactinemia in women: treatment
Rev Bras Ginecol Obstet. 2024;46:e-FPS05
Views692Summary
Febrasgo Position StatementHyperprolactinemia in women: treatment
Rev Bras Ginecol Obstet. 2024;46:e-FPS05
- Cristina Laguna Benetti-Pinto
-
Febrasgo Position Statement
Breech birth care: Number 1 – 2024
- Álvaro Luiz Lage Alves ,
- Alexandre Massao Nozaki ,
- Carla Betina Andreucci Polido ,
- Lucas Barbosa da Silva ,
- Roxana Knobel
Summary
Febrasgo Position StatementBreech birth care: Number 1 – 2024
Rev Bras Ginecol Obstet. 2024;46:e-rbgofps1
Views550Summary
Febrasgo Position StatementBreech birth care: Number 1 – 2024
Rev Bras Ginecol Obstet. 2024;46:e-rbgofps1
- Álvaro Luiz Lage Alves
-
Letter to the Editor
Letter to Editor: In response to existence of SARS-CoV-2 in the peritoneal fluid
- Gustavo Romero-Velez ,
- Guillermo Ponce de Leon-Ballesteros ,
- Juan Barajas-Gamboa ,
- Jerry Dang ,
- Andrew Strong , [ … ],
- Mathew Kroh
Summary
Letter to the EditorLetter to Editor: In response to existence of SARS-CoV-2 in the peritoneal fluid
Rev Bras Ginecol Obstet. 2024;46:e-rbgo24
Views539Summary
Letter to the EditorLetter to Editor: In response to existence of SARS-CoV-2 in the peritoneal fluid
Rev Bras Ginecol Obstet. 2024;46:e-rbgo24
- Gustavo Romero-Velez
-
The path to elimination: FEBRASGO 2023’s targeted strategies against cervical cancer in Brazil
- Agnaldo Lopes da Silva Filho ,
- Cecilia Maria Roteli-Martins ,
- Neila Maria de Góis Speck ,
- Newton Sérgio de Carvalho ,
- Eduardo Batista Cândido , [ … ],
- Júlio César Teixeira
- Agnaldo Lopes da Silva Filho
-
Early and late-onset preeclampsia: effects of DDAH2 polymorphisms on ADMA levels and association with DDAH2 haplotypes
- Fernanda Santos Mendes ,
- Marcelo Rizzatti Luizon ,
- Ana Cristina dos Santos Lopes ,
- Daniela Alves Pereira ,
- Fernanda Cristina Gontijo Evangelista , [ … ],
- Patrícia Nessralla Alpoim
Summary
Early and late-onset preeclampsia: effects of DDAH2 polymorphisms on ADMA levels and association with DDAH2 haplotypes
Rev Bras Ginecol Obstet. 2024;46:e-rbgo19
- Fernanda Santos Mendes ,
- Marcelo Rizzatti Luizon ,
- Ana Cristina dos Santos Lopes ,
- Daniela Alves Pereira ,
- Fernanda Cristina Gontijo Evangelista ,
- Lara Carvalho Godoi ,
- Luci Maria Dusse ,
- Patrícia Nessralla Alpoim
Views230Abstract
Objective:
To examine whether the DDAH2 promoter polymorphisms -1415G/A (rs2272592), -1151A/C (rs805304) and -449G/C (rs805305), and their haplotypes, are associated with PE compared with normotensive pregnant women, and whether they affect ADMA levels in these groups.
Methods:
A total of 208 pregnant women were included in the study and classified as early-onset (N=57) or late-onset PE (N =49), and as normotensive pregnant women (N = 102).
Results:
Pregnant with early-onset PE carrying the GC and GG genotypes for the DDAH2 -449G/C polymorphism had increased ADMA levels (P=0.01). No association of DDAH2 polymorphisms with PE in single-locus analysis was found. However, the G-C-G haplotype was associated with the risk for late-onset PE.
Conclusion:
It is suggested that DDAH2 polymorphisms could affect ADMA levels in PE, and that DDAH2 haplotypes may affect the risk for PE.
Key-words Asymmetric dimethylarginineDimethylarginine dimethylaminohydrolase 2 geneGenotypeHaplotypesNitric Oxide SynthaseNitric Oxide Synthase Type III/ geneticsPolymorphism, geneticpre-eclampsiapregnant womenSee moreViews230Summary
Early and late-onset preeclampsia: effects of DDAH2 polymorphisms on ADMA levels and association with DDAH2 haplotypes
Rev Bras Ginecol Obstet. 2024;46:e-rbgo19
- Fernanda Santos Mendes ,
- Marcelo Rizzatti Luizon ,
- Ana Cristina dos Santos Lopes ,
- Daniela Alves Pereira ,
- Fernanda Cristina Gontijo Evangelista ,
- Lara Carvalho Godoi ,
- Luci Maria Dusse ,
- Patrícia Nessralla Alpoim
Views230Abstract
Objective:
To examine whether the DDAH2 promoter polymorphisms -1415G/A (rs2272592), -1151A/C (rs805304) and -449G/C (rs805305), and their haplotypes, are associated with PE compared with normotensive pregnant women, and whether they affect ADMA levels in these groups.
Methods:
A total of 208 pregnant women were included in the study and classified as early-onset (N=57) or late-onset PE (N =49), and as normotensive pregnant women (N = 102).
Results:
Pregnant with early-onset PE carrying the GC and GG genotypes for the DDAH2 -449G/C polymorphism had increased ADMA levels (P=0.01). No association of DDAH2 polymorphisms with PE in single-locus analysis was found. However, the G-C-G haplotype was associated with the risk for late-onset PE.
Conclusion:
It is suggested that DDAH2 polymorphisms could affect ADMA levels in PE, and that DDAH2 haplotypes may affect the risk for PE.
Key-words Asymmetric dimethylarginineDimethylarginine dimethylaminohydrolase 2 geneGenotypeHaplotypesNitric Oxide SynthaseNitric Oxide Synthase Type III/ geneticsPolymorphism, geneticpre-eclampsiapregnant womenSee more
- Fernanda Santos Mendes
-
Febrasgo Position Statement
Use of hormones and risk of venous thromboembolism
- Venina Isabel Poço Viana Leme de Barros ,
- André Luiz Malavasi Longo de Oliveira ,
- Denis Jose do Nascimento ,
- Eduardo Zlotnik ,
- Marcelo Melzer Teruchkin , [ … ],
- Paulo Francisco Ramos Margarido
Summary
Febrasgo Position StatementUse of hormones and risk of venous thromboembolism
Rev Bras Ginecol Obstet. 2024;46:e-FPS02
- Venina Isabel Poço Viana Leme de Barros ,
- André Luiz Malavasi Longo de Oliveira ,
- Denis Jose do Nascimento ,
- Eduardo Zlotnik ,
- Marcelo Melzer Teruchkin ,
- Marcos Arêas Marques ,
- Paulo Francisco Ramos Margarido
Views228See moreKey points
•The risk of venous thromboembolism (VTE) is not increased in women using long-acting reversible contraceptive methods (LARCs) with progestogens.
•Oral contraceptives with levonorgestrel or norgestimate confer half the risk of VTE compared to oral contraceptives containing desogestrel, gestodene or drospirenone.
•Progestogen-only pills do not confer an increased risk of VTE.
•Women using transdermal contraceptive patches and combined oral contraceptives (COCs) are at an approximately eight times greater risk of VTE than non-users of hormonal contraceptives (HCs), corresponding to 9.7 events per 10,000 women/years.
•Vaginal rings increase the risk of VTE by 6.5 times compared to not using HC, corresponding to 7.8 events per 10,000 women/years.
•Several studies have demonstrated an increased risk of VTE in transgender individuals receiving hormone therapy (HT).
•Hormone therapy during menopause increases the risk of VTE by approximately two times, and this risk is increased by obesity, thrombophilia, age over 60 years, surgery and immobilization.
•The route of estrogen administration, the dosage and type of progestogen associated with estrogen may affect the risk of VTE in the climacteric.
•Combined estrogen-progesterone therapy increases the risk of VTE compared to estrogen monotherapy.
•Postmenopausal HT increases the risk of thrombosis at atypical sites.
Views228Summary
Febrasgo Position StatementUse of hormones and risk of venous thromboembolism
Rev Bras Ginecol Obstet. 2024;46:e-FPS02
- Venina Isabel Poço Viana Leme de Barros ,
- André Luiz Malavasi Longo de Oliveira ,
- Denis Jose do Nascimento ,
- Eduardo Zlotnik ,
- Marcelo Melzer Teruchkin ,
- Marcos Arêas Marques ,
- Paulo Francisco Ramos Margarido
Views228See moreKey points
•The risk of venous thromboembolism (VTE) is not increased in women using long-acting reversible contraceptive methods (LARCs) with progestogens.
•Oral contraceptives with levonorgestrel or norgestimate confer half the risk of VTE compared to oral contraceptives containing desogestrel, gestodene or drospirenone.
•Progestogen-only pills do not confer an increased risk of VTE.
•Women using transdermal contraceptive patches and combined oral contraceptives (COCs) are at an approximately eight times greater risk of VTE than non-users of hormonal contraceptives (HCs), corresponding to 9.7 events per 10,000 women/years.
•Vaginal rings increase the risk of VTE by 6.5 times compared to not using HC, corresponding to 7.8 events per 10,000 women/years.
•Several studies have demonstrated an increased risk of VTE in transgender individuals receiving hormone therapy (HT).
•Hormone therapy during menopause increases the risk of VTE by approximately two times, and this risk is increased by obesity, thrombophilia, age over 60 years, surgery and immobilization.
•The route of estrogen administration, the dosage and type of progestogen associated with estrogen may affect the risk of VTE in the climacteric.
•Combined estrogen-progesterone therapy increases the risk of VTE compared to estrogen monotherapy.
•Postmenopausal HT increases the risk of thrombosis at atypical sites.
- Venina Isabel Poço Viana Leme de Barros
-
Febrasgo Position Statement
Vulvovaginitis in pregnant women
- Geraldo Duarte ,
- Iara Moreno Linhares ,
- Regis Kreitchmann ,
- Andréa da Rocha Tristão ,
- Evelyn Traina , [ … ],
- Joelma Queiroz Andrade
Summary
Febrasgo Position StatementVulvovaginitis in pregnant women
Rev Bras Ginecol Obstet. 2024;46:e-FPS03
- Geraldo Duarte ,
- Iara Moreno Linhares ,
- Regis Kreitchmann ,
- Andréa da Rocha Tristão ,
- Evelyn Traina ,
- Ivete Canti ,
- Marcos Takimura ,
- Joelma Queiroz Andrade
Views225See moreKey points
• The balanced vaginal microbiome is the main factor defending the vaginal environment against infections. Lactobacilli play a key role in this regard, maintaining the vaginal pH within the normal range (3.8 to 4.5).
•Hormonal and immune adaptations resulting from pregnancy influence changes in the vaginal microbiome during pregnancy.
•An altered vaginal microbiome predisposes to human immunodeficiency virus (HIV) infection.
•Bacterial vaginosis is the main clinical expression of an imbalanced vaginal microbiome.
•Vulvovaginal candidiasis depends more on the host’s conditions than on the etiological agent.
•Trichomonas vaginalis is a protozoan transmitted during sexual intercourse.
•The use of probiotics is not approved for use in pregnant women.
Views225Summary
Febrasgo Position StatementVulvovaginitis in pregnant women
Rev Bras Ginecol Obstet. 2024;46:e-FPS03
- Geraldo Duarte ,
- Iara Moreno Linhares ,
- Regis Kreitchmann ,
- Andréa da Rocha Tristão ,
- Evelyn Traina ,
- Ivete Canti ,
- Marcos Takimura ,
- Joelma Queiroz Andrade
Views225See moreKey points
• The balanced vaginal microbiome is the main factor defending the vaginal environment against infections. Lactobacilli play a key role in this regard, maintaining the vaginal pH within the normal range (3.8 to 4.5).
•Hormonal and immune adaptations resulting from pregnancy influence changes in the vaginal microbiome during pregnancy.
•An altered vaginal microbiome predisposes to human immunodeficiency virus (HIV) infection.
•Bacterial vaginosis is the main clinical expression of an imbalanced vaginal microbiome.
•Vulvovaginal candidiasis depends more on the host’s conditions than on the etiological agent.
•Trichomonas vaginalis is a protozoan transmitted during sexual intercourse.
•The use of probiotics is not approved for use in pregnant women.
- Geraldo Duarte
Search
Search in:
Tag Cloud
breast (42) breast cancer (42) breast neoplasms (95) Cesarean section (72) endometriosis (66) infertility (56) Maternal mortality (43) menopause (82) obesity (58) postpartum period (40) pregnancy (225) Pregnancy complications (99) Prenatal care (68) prenatal diagnosis (50) Prevalence (41) Quality of life (51) risk factors (94) ultrasonography (79) urinary incontinence (40) women's health (48)
Featured Articles
- Febrasgo Position Statement
Hyperprolactinemia in women: diagnostic approach
- Andrea Glezer ,
- Heraldo Mendes Garmes ,
- Leandro Kasuki ,
- Manoel Martins ,
- Paula Condé Lamparelli Elias ,
- Vania dos Santos Nunes Nogueira ,
- Ana Carolina Japur de Sá Rosa-e-Silva ,
- Gustavo Arantes Rosa Maciel ,
- Cristina Laguna Benetti-Pinto ,
- Andrea Prestes Nácul
Summary
Febrasgo Position StatementHyperprolactinemia in women: diagnostic approach
Rev Bras Ginecol Obstet. 2024;46:e-FPS04
Views701Summary
Febrasgo Position StatementHyperprolactinemia in women: diagnostic approach
Rev Bras Ginecol Obstet. 2024;46:e-FPS04
- Andrea Glezer
- Febrasgo Position Statement
Hyperprolactinemia in women: treatment
- Cristina Laguna Benetti-Pinto ,
- Andrea Prestes Nácul ,
- Ana Carolina Japur Rosa e Silva ,
- Gustavo Arantes Rosa Maciel ,
- Vania dos Santos Nunes Nogueira ,
- Paula Condé Lamparelli Elias ,
- Manoel Martins ,
- Leandro Kasuki ,
- Heraldo Mendes Garmes ,
- Andrea Glezer
Summary
Febrasgo Position StatementHyperprolactinemia in women: treatment
Rev Bras Ginecol Obstet. 2024;46:e-FPS05
Views692Summary
Febrasgo Position StatementHyperprolactinemia in women: treatment
Rev Bras Ginecol Obstet. 2024;46:e-FPS05
- Cristina Laguna Benetti-Pinto
- Original Article
Comparison of Cavum Septum Pellucidum Size in Euploid and Aneuploid Fetuses
Rev Bras Ginecol Obstet. 2023;45(9):511-516Summary
Original ArticleComparison of Cavum Septum Pellucidum Size in Euploid and Aneuploid Fetuses
Rev Bras Ginecol Obstet. 2023;45(9):511-516
Views13See moreAbstract
Objective
The aim of the present study is to compare the cavum septum pellucidi (CSP) z-score in euploid and aneuploid fetuses and to investigate the performance of the CSP width/length and CSP width/biparietal diameter (BPD) ratios as a diagnostic marker in aneuploidy.
Methods
A total of 54 patients, 20 aneuploid and 35 euploid fetuses, between 18 and 37 weeks of gestation, were included in this retrospective study. The CSP width z-score was compared between the two groups. Receiver operating characteristic (ROC) curves were calculated for the CSP width/length and CSP width/BPD ratios to predict aneuploidy.
Results
The median CSP width was 4.8 mm (range, 1.8 to 8.5 mm) in the euploid group, and 5.4 mm (range 3.1 to 8.4 mm) in the aneuploid group. Cavum septum pellucidi width z-score, CSP width/length ratio, and CSP width/BPD ratio were significantly higher in fetuses with aneuploidy than in fetuses with normal karyotype (p = 0.001; p = 0.013; p = 0.028). In the ROC analysis, the CSP width/length ratio had the optimal cutoff value of 0.59, with 72.0% sensitivity and 58.0% specificity, and for the CSP width/BPD ratio, the cutoff value was 0.081 with 83.0% sensitivity and 61.0% specificity for detection of aneuploidy.
Conclusion
CSP width z-score was found to be increased in aneuploid fetuses. The CSP width /BPD ratio can be used as a new marker for predicting aneuploidy.
Views13Summary
Original ArticleComparison of Cavum Septum Pellucidum Size in Euploid and Aneuploid Fetuses
Rev Bras Ginecol Obstet. 2023;45(9):511-516
Views13See moreAbstract
Objective
The aim of the present study is to compare the cavum septum pellucidi (CSP) z-score in euploid and aneuploid fetuses and to investigate the performance of the CSP width/length and CSP width/biparietal diameter (BPD) ratios as a diagnostic marker in aneuploidy.
Methods
A total of 54 patients, 20 aneuploid and 35 euploid fetuses, between 18 and 37 weeks of gestation, were included in this retrospective study. The CSP width z-score was compared between the two groups. Receiver operating characteristic (ROC) curves were calculated for the CSP width/length and CSP width/BPD ratios to predict aneuploidy.
Results
The median CSP width was 4.8 mm (range, 1.8 to 8.5 mm) in the euploid group, and 5.4 mm (range 3.1 to 8.4 mm) in the aneuploid group. Cavum septum pellucidi width z-score, CSP width/length ratio, and CSP width/BPD ratio were significantly higher in fetuses with aneuploidy than in fetuses with normal karyotype (p = 0.001; p = 0.013; p = 0.028). In the ROC analysis, the CSP width/length ratio had the optimal cutoff value of 0.59, with 72.0% sensitivity and 58.0% specificity, and for the CSP width/BPD ratio, the cutoff value was 0.081 with 83.0% sensitivity and 61.0% specificity for detection of aneuploidy.
Conclusion
CSP width z-score was found to be increased in aneuploid fetuses. The CSP width /BPD ratio can be used as a new marker for predicting aneuploidy.
Aims and Vision
The Brazilian Journal of Gynecology and Obstetrics (RBGO) aims to publish basic and clinical research in gynecology, obstetrics and other related specialties and be a reference to support and promote professional education for residents, researchers and university teachers. As a vision, RBGO aims to become an internationally recognized reference among the main world’s journals in Gynecology and Obstetrics.
